in this issue
People & Business :: Emerging Companies
Enzon Pharmaceuticals to Spin Off Unit
May 19, 2008 | Deepti Ramesh
Enzon Pharmaceuticals (Bridgewater, NJ) says it plans to spin off its novel biotechnology business to create separate biotechnology and speciality pharmaceutical public companies. The transaction is expected to be completed in the fourth quarter. “The opportunities for both the specialty pharmaceutical business and the biotechnology business could be substantially enhanced, and greater value could be created than under the current structure,” says Jeffrey Buchalter, chairman, president, and CEO of Enzon. “Operating separately will allow each...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee